Stock Market & Financial Investment News

News Breaks February 22, 2013 11:34 EDT SRPT Sarepta Therapeutics volatility elevated into Q4 Sarepta Therapeutics December call option implied volatility is at 123, April is at 131, May is at 119; compared to its 26-week average of 103 according to Track Data, suggesting larger price movement into the expected release of Q4 results on March 7. News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 11:13 EDT SRPT Sarepta rises after reporting clinical data Subscribe for More Information 09:54 EDT SRPT Sarepta data supports accelerated approval, says Piper Jaffray Subscribe for More Information 08:39 EDT SRPT Sarepta eteplirsen demonstrates benefit on walking test in Phase IIb study Sarepta Therapeutics announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy, or DMD. Results at 84 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test. As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51. June 17, 2013 12:20 EDT SRPT Options with increasing implied volatility: WLT LNCO SRPT LINE Subscribe for More Information June 14, 2013 11:23 EDT SRPT Options with increasing implied volatility: TWO SRPT LNCO LINE DVA 06:15 EDT SRPT Leerink remains cautious on accelerated approval for Sarepta Subscribe for More Information June 5, 2013 13:29 EDT SRPT Options with decreasing implied volatility: INFI SRPT GES SUPN CPRT Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.